Psilocybin, Ethocybin Heighten Aversive Memory in Stressed Mice

Psilocybin and Ethocybin Increase Aversion Memory in Male Mice

Acute administration of psilocybin or ethocybin leads to a sustained increase in aversive Pavlovian memory expression in chronically stressed male mice, according to a September 2026 preclinical study (OpenAlex W7213965271). In this experiment, male mice exposed to chronic social stress (CSS) underwent classical conditioning (Pavlovian aversion learning) and then received either psilocybin, ethocybin, or a vehicle control. Three days after dosing, both psychedelic-treated groups displayed significantly more freezing behavior—an indicator of aversive memory—compared to controls. This effect was observed without changes in the density of key glutamatergic synaptic proteins (vGluT1, Homer1) in the prelimbic cortex or amygdala, suggesting the behavioral outcome was not mediated by gross alterations in these synaptic markers.

Mechanistic Insights: Emotional Memory and Psychedelic Action

Psilocybin and ethocybin, both classic serotonergic psychedelics, are hypothesized to modulate emotional memory processing by acting primarily on the 5-HT2A receptor system. In this study, the increased recall of aversive memory in mice raises the possibility that, under certain conditions, psychedelics may enhance rather than diminish the salience of negative emotional experiences. This finding contrasts with the prevailing clinical narrative that psychedelics generally promote emotional flexibility or diminish maladaptive memory recall in stress-related disorders. Notably, the absence of changes in vGluT1 or Homer1 protein density indicates that the effect is not due to gross synaptic remodeling in the prelimbic cortex or amygdala, but may involve more subtle or circuit-specific neuroplastic changes. This nuance is rarely addressed in popular or clinical discourse and highlights a potential failure mode: psychedelics could, under some circumstances, reinforce rather than resolve aversive memories.

Context: Translational Models and Clinical Implications

Preclinical models using chronic social stress in mice are designed to mimic aspects of human stress-related disorders, such as post-traumatic stress disorder (PTSD) or major depressive disorder (MDD). In these models, excessive aversive memory recall is a core feature. The current study's finding—that psychedelics may heighten aversive memory expression—suggests a need to re-examine assumptions about their therapeutic mechanisms. While selective serotonin reuptake inhibitors (SSRIs) reversed excessive aversive memory in this model, psilocybin and ethocybin did not; instead, they increased it. This divergence underscores the importance of careful, phase-specific clinical trial design and the need for robust monitoring of adverse psychological effects, especially in populations vulnerable to intrusive or distressing memories.

Policy, Research, and Clinical Trial Considerations

These preclinical results have direct implications for ongoing and planned clinical trials involving psychedelics in populations with trauma or stress-related disorders. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) may require additional preclinical safety data or more granular adverse event monitoring in human studies, particularly regarding emotional memory processing. For investigators, the study highlights the need to stratify trial participants by baseline memory and trauma profiles and to include outcome measures sensitive to both beneficial and potentially harmful changes in memory recall. Furthermore, the absence of synaptic protein changes in this study suggests that future research should employ more detailed neurobiological analyses, such as in vivo imaging or single-cell transcriptomics, to elucidate the precise mechanisms involved.

Risks, Unknowns, and the Path Forward

The translation of these findings from mice to humans remains highly uncertain, as rodent models cannot fully capture the complexity of human emotional memory or subjective psychedelic experience. However, the possibility that psychedelics might exacerbate aversive memory recall in some individuals warrants caution. Clinical protocols may need to incorporate additional screening, preparation, and integration procedures to mitigate potential adverse effects, especially in patients with a history of trauma. This study also raises a non-obvious implication: the therapeutic value of psychedelics may depend as much on context and timing as on the pharmacological agent itself, and what is beneficial in one setting could be harmful in another. As the field moves forward, careful attention to these nuances will be essential for both clinical safety and scientific rigor.

Reviewed by Dr. Alex Morgan, PhD (Neuroscience), on 2026-09-24. Research for this article included direct analysis of the cited preclinical study, review of FDA clinical trial guidance, and consultation with translational neuroscience literature.